iX Biopharma (SGX:42C) Moat Score: 0/10 (As of Aug. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGX:42C iX Biopharma Ltd SGX:42C
36 GF Score
Price S$0.55
GF Value S$0.03
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is iX Biopharma Moat Score?

iX Biopharma has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

iX Biopharma has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes iX Biopharma might have No Moat - No discernible moat.

iX Biopharma  (SGX:42C) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

iX Biopharma Moat Score Related Terms

SGX:42C
36GF Score
iX Biopharma Ltd SGX:42C
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is iX Biopharma (SGX:42C) Overvalued in 2026?

Based on GuruFocus' analysis, iX Biopharma stock appears to be overvalued. The current stock price of S$0.55 is trading 1716.7% above its estimated GF Value™ of S$0.03. GuruFocus considers iX Biopharma to be Significantly Overvalued.

Key valuation signals for SGX:42C:

  • Moat Score: 0
  • GF Value™: S$0.03 vs. price of S$0.55 (1716.7% above fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the SGX:42C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

iX Biopharma Business Description

Address 1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are the Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in the United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.
36GF Score

Get the complete analysis for SGX:42C

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

S$0.55
Price
S$0.03
GF Value